There isn't one in any meaningful pharmacological sense. Vitamin K is a structural/long-term supplement; it has no acute psychoactive, cognitive, or somatic effect noticeable on the timescale of hours or days. Users who report "energy" or "focus" after MK-7 are almost certainly experiencing the D3 they paired it with, or confirmation bias.

Where users do notice something subjectively over weeks to months at adequate dose:

• Reduced "bone bruising" recovery time after impact — common report among combat athletes and weightlifters who started high-dose D3 + K2 stacks. Mechanism plausible (osteocalcin activation) but not RCT-tested.
• Calmer cardiac feel on D3-heavy stacks — some users on 5000 IU D3 + calcium without K2 report palpitations or chest tightness that resolve after adding K2-MK7 90-180 mcg. Mechanism unclear; could be coincident magnesium adequacy or true MGP-mediated effect on vascular tone.
• Reduced morning stiffness in 40+ users with osteoarthritis — anecdotal, attributed to cartilage Gla-protein and MGP carboxylation.
• Heavier menstrual bleeding at >360 mcg/day MK-7 in a subset of women — rare, reverses with dose reduction; mechanistically inconsistent with K's pro-clotting role but reported.

Honest framing: K2 is a maintenance vitamin, not a felt supplement. Anyone selling MK-7 as "energy" or "focus" is wrong. Anyone selling it as "the missing piece of your D3 stack for long-term arterial and bone protection" is closer to the data.

No pharmacological tolerance. Vitamin K is a cofactor consumed in a one-pass redox cycle and recycled; receptor downregulation isn't a concept here. dp-ucMGP and ucOC reach a new steady-state within ~2-4 weeks of supplementation and stay there as long as intake continues. Stop intake and dp-ucMGP climbs back toward baseline over 2-6 weeks as VKDPs accumulate uncarboxylated.

Cycling is unnecessary and counterproductive. This is a continuous-maintenance supplement. Intermittent dosing wastes the long half-life advantage of MK-7 and lets dp-ucMGP drift. The only reasonable reason to pause is a planned surgical procedure with surgeon-requested K washout.

Tachyphylaxis: none reported. Receptor systems aren't relevant.

Withdrawal: none. Cessation produces a slow drift toward pre-supplementation biomarker baseline over weeks, with no symptoms.

Synergistic with:

• Vitamin D3 — the canonical pairing. D3 raises calcium absorption and upregulates osteocalcin/MGP transcription; K2 carboxylates them. Use 90-180 mcg MK-7 per 5000 IU D3 as a baseline. Many quality products (Thorne, NOW, Nordic Naturals, LifeExtension) ship the combo in a single capsule.
• Magnesium glycinate or malate (200-400 mg/day) — magnesium is a cofactor for both D3 activation (1-alpha-hydroxylase) and for ATP-dependent calcium handling. D3 + Ca + K2 without adequate Mg is incomplete.
• Calcium (food-first, supplement only if intake <800 mg/day) — K2 is what makes calcium supplementation safer; the residual debate over calcium-supplement-driven CVD signal (Bolland 2010) is largely about calcium given without K2.
• Boron (3 mg/day) and vitamin K2 — boron influences VDR signalling and calcium handling; weak mechanistic synergy.
• Omega-3 EPA/DHA — vascular health hub. No direct K interaction; both contribute to arterial wall biology from different angles.
• Resveratrol, curcumin, taurine — generic vascular co-supplements; no specific K interaction but compatible.

Compatible but neutral:

• Most nootropics: modafinil, racetams, citicoline, alpha-GPC, ashwagandha, rhodiola — zero K interaction.
• Creatine, beta-alanine, electrolytes — neutral.
• Selank, Semax, BPC-157, peptides generally — neutral.

Avoid stacking with:

• Warfarin and other vitamin K antagonists (acenocoumarol, phenprocoumon) — strict contraindication unless directed by anticoagulation clinic. Even consistent supplementation can be tolerated if INR is monitored and warfarin is re-titrated, but adding/removing K supplements during stable warfarin therapy is the classic INR-destabilising error.
• Atorvastatin (and other statins) — caution, not contraindication. Statins inhibit HMG-CoA reductase and the mevalonate pathway that supplies geranylgeranyl precursors used to convert K1 to tissue MK-4. Mechanistically suggests long-term statin users may have lower tissue K2 status and benefit from MK-7 supplementation. Hypothesis-generating; no hard RCT evidence yet.

• Warfarin (Coumadin) — CONTRAINDICATED. Warfarin's entire mechanism is VKORC1 inhibition, depleting active vitamin K. Adding supplemental K bypasses this block via alternative reduction pathways and reverses anticoagulation, rapidly dropping INR and raising thromboembolic risk. The clinical rule for warfarin patients is consistent dietary K intake, not zero intake; supplemental K-MK7 90-180 mcg is enough to destabilise a warfarin-titrated INR. Do not add unless your anticoagulation clinic agrees and re-titrates warfarin.
• Acenocoumarol, phenprocoumon — same mechanism, same rule.
• Direct oral anticoagulants (DOACs): apixaban, rivaroxaban, edoxaban, dabigatran — NO interaction. These inhibit factor Xa or thrombin directly downstream of K-dependent factor synthesis. Vitamin K supplementation does not affect their anticoagulant effect. Patients switched from warfarin to a DOAC can resume K2 supplementation safely.
• Antibiotics (broad-spectrum, prolonged) — long courses of cephalosporins with NMTT side chain (cefamandole, cefoperazone) or rifampin can suppress gut microbial menaquinone production and produce mild K deficiency. Generally not clinically relevant unless dietary K is also low.
• Bile acid sequestrants (cholestyramine, colestipol) and orlistat — reduce K absorption by interfering with fat-soluble vitamin uptake. Separate dosing by 4+ hours or supplement.
• Statins (especially atorvastatin) — mechanistic concern (mevalonate pathway suppression reduces K1→MK-4 conversion); no contraindication but argues for direct MK-7 supplementation in long-term statin users.
• Mineral oil, olestra — chronic use reduces fat-soluble vitamin absorption.
• High-dose vitamin E (>800 IU) — competitive interaction; very high E can mildly antagonise K-dependent clotting. Rarely clinically relevant; matters if combined with anticoagulation.
• Glucocorticoids long-term — bone-loss risk amplifies the rationale for K2 + D3 supplementation; no direct PK interaction.

Vitamin K metabolism has a small but interesting pharmacogenomic landscape, mostly studied in warfarin dosing rather than K2 supplementation specifically.

• VKORC1 (-1639G>A, rs9923231) — the VKORC1 promoter variant is the single largest genetic determinant of warfarin sensitivity. A-allele carriers have lower VKORC1 expression, less K-recycling capacity, and require lower warfarin doses. For K2 supplementation in non-warfarin users: A-carriers may have slightly more uncarboxylated VKDPs at baseline (less efficient recycling) and theoretically benefit more from supplementation. Hypothesis-generating; no direct trial data.
• CYP4F2 V433M (rs2108622) — the V433M variant reduces hepatic CYP4F2 capacity to oxidatively degrade K1, raising steady-state K1 levels. T-allele carriers require ~8% higher warfarin doses (McDonald 2009, PMID 19297519). For K2 supplementation this is a non-issue clinically.
• **CYP2C9 2 and 3 — affects warfarin clearance, not K vitamers directly.
• GGCX polymorphisms — rare variants exist; severe forms produce pseudoxanthoma-elasticum-like vascular calcification phenotypes. Common variants modestly affect carboxylation efficiency.
• APOE genotype — APOE4 carriers have altered lipoprotein trafficking, which affects K1 hepatic uptake and MK-7 extra-hepatic distribution. APOE4 carriers may need higher MK-7 doses to achieve equivalent dp-ucMGP reduction; data is exploratory.
• MTHFR C677T — no direct K interaction, but coexists in many users on D3+K2 stacks via the methylation/cardio nexus.

For Dylan's archetype: 23andMe results (due June 2026) will surface VKORC1, CYP4F2, CYP2C9 and APOE status. None of these change the recommendation to take 90-180 mcg MK-7 daily; they would only matter if warfarin enters the picture decades from now.

Default recommendation: MenaQ7 or K2VITAL trans-MK-7 at 90-180 mcg/day, in a D3+K2 combo if minimising pill count, or standalone alongside D3 if dose flexibility matters. Sourcing is easy and cheap; no gray-market work needed.

Specifically avoid:

• "Vitamin K" products that don't specify K1 vs K2 vs the menaquinone subtype.
• Products containing menadione (synthetic K3) — toxicity history, never used in modern supplements but occasionally surfaces in cheap multivitamins.
• Cis-isomer MK-7 contamination — products without an explicit "≥99% trans" or MenaQ7/K2VITAL designation.
• "K2 complex" blends that list MK-7 at <45 mcg per dose hidden inside a 30-ingredient formula.

Dylan specifically: dp-ucMGP is the cleanest tracker if available; otherwise just monitor 25(OH)D and serum calcium with annual bloodwork. CAC at 40 is the relevant cardiac downstream marker.